Quanterix Unveils Landmark Study Showing Multi-Biomarker Blood Test Improves Early Alzheimer’s Risk Profiling

Reuters01-21

Quanterix Unveils Landmark Study Showing Multi-Biomarker Blood Test Improves Early Alzheimer’s Risk Profiling

Quanterix Corporation has announced the publication of a new clinical study in JAMA Network Open, led by researchers at Amsterdam UMC, which followed a cohort of nearly 300 individuals for up to 15 years. The study demonstrated that combining multiple blood-based biomarkers—specifically amyloid, tau, neurodegeneration, and neuroinflammation—along with their longitudinal trajectories, provides a more comprehensive assessment of Alzheimer’s disease risk at the earliest stages compared to individual biomarkers alone. The study results have already been published and are accessible in the journal. Quanterix’s Simoa® technology and multiplexed biomarker assays were used in the study, and the company has introduced the LucentAD Complete test, which incorporates the same biomarkers evaluated in the research, offering an overall amyloid risk score and individual biomarker results for symptomatic individuals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260121870977) on January 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605107054?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-21 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605107054","market":"nz","top_or_hot":-1,"title":"Quanterix Unveils Landmark Study Showing Multi-Biomarker Blood Test Improves Early Alzheimer’s Risk Profiling","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Quanterix Unveils Landmark Study Showing Multi-Biomarker Blood Test Improves Early Alzheimer’s Risk Profiling\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quanterix Corporation has announced the publication of a new clinical study in JAMA Network Open, led by researchers at Amsterdam UMC, which followed a cohort of nearly 300 individuals for up to 15 years. The study demonstrated that combining multiple blood-based biomarkers—specifically amyloid, tau, neurodegeneration, and neuroinflammation—along with their longitudinal trajectories, provides a more comprehensive assessment of Alzheimer’s disease risk at the earliest stages compared to individual biomarkers alone. The study results have already been published and are accessible in the journal. Quanterix’s Simoa® technology and multiplexed biomarker assays were used in the study, and the company has introduced the LucentAD Complete test, which incorporates the same biomarkers evaluated in the research, offering an overall amyloid risk score and individual biomarker results for symptomatic individuals.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260121870977) on January 21, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quanterix Unveils Landmark Study Showing Multi-Biomarker Blood Test Improves Early Alzheimer’s Risk Profiling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuanterix Unveils Landmark Study Showing Multi-Biomarker Blood Test Improves Early Alzheimer’s Risk Profiling\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-21 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Quanterix Unveils Landmark Study Showing Multi-Biomarker Blood Test Improves Early Alzheimer’s Risk Profiling\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quanterix Corporation has announced the publication of a new clinical study in JAMA Network Open, led by researchers at Amsterdam UMC, which followed a cohort of nearly 300 individuals for up to 15 years. The study demonstrated that combining multiple blood-based biomarkers—specifically amyloid, tau, neurodegeneration, and neuroinflammation—along with their longitudinal trajectories, provides a more comprehensive assessment of Alzheimer’s disease risk at the earliest stages compared to individual biomarkers alone. The study results have already been published and are accessible in the journal. Quanterix’s Simoa® technology and multiplexed biomarker assays were used in the study, and the company has introduced the LucentAD Complete test, which incorporates the same biomarkers evaluated in the research, offering an overall amyloid risk score and individual biomarker results for symptomatic individuals.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260121870977) on January 21, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDLdPGnP:1","article_id":"2605107054","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605107054","pubTimestamp":1769002394,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Quanterix Corporation has announced the publication of a new clinical study in JAMA Network Open, led by researchers at Amsterdam UMC, which followed a cohort of nearly 300 individuals for up to 15 years. The study demonstrated that combining multiple blood-based biomarkers—specifically amyloid, tau, neurodegeneration, and neuroinflammation—along with their longitudinal trajectories, provides a more comprehensive assessment of Alzheimer’s disease risk at the earliest stages compared to individual biomarkers alone. The study results have already been published and are accessible in the journal. Quanterix’s Simoa technology and multiplexed biomarker assays were used in the study, and the company has introduced the LucentAD Complete test, which incorporates the same biomarkers evaluated in the research, offering an overall amyloid risk score and individual biomarker results for symptomatic individuals.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","QTRX":"Quanterix Corp"},"translate_title":"Quanterix公布具有里程碑意义的研究，表明多生物标志物血液测试可改善早期阿尔茨海默病的风险状况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QTRX":0.9},"content_text":"Quanterix Unveils Landmark Study Showing Multi-Biomarker Blood Test Improves Early Alzheimer’s Risk Profiling\n    \n\n        Quanterix Corporation has announced the publication of a new clinical study in JAMA Network Open, led by researchers at Amsterdam UMC, which followed a cohort of nearly 300 individuals for up to 15 years. The study demonstrated that combining multiple blood-based biomarkers—specifically amyloid, tau, neurodegeneration, and neuroinflammation—along with their longitudinal trajectories, provides a more comprehensive assessment of Alzheimer’s disease risk at the earliest stages compared to individual biomarkers alone. The study results have already been published and are accessible in the journal. Quanterix’s Simoa® technology and multiplexed biomarker assays were used in the study, and the company has introduced the LucentAD Complete test, which incorporates the same biomarkers evaluated in the research, offering an overall amyloid risk score and individual biomarker results for symptomatic individuals.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260121870977) on January 21, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605107054","isCrawlerRequest":true}